Work

Successful use of angiotensin II for vasoplegia after thoracoabdominal aortic aneurysm repair

Year: 2020

Type: article

Abstract: Vasoplegic shock, or vasoplegia, features refractory hypotension, high cardiac output, and low systemic vascular resistance. Typically, for patients who undergo thoracoabdominal aortic aneurysm repair (TAAAR), fluids and vasopressors are used to maintain a target mean arterial pressure (MAP) of 80 to 100 mm Hg to prevent spinal cord ischemia. Spinal cord deficit (SCD) is among the most feared complications after Crawford extent II TAAAR, with an incidence of approximately 8%.1 We describe a novel case in which angiotensin II (AngII; Giapreza, La Jolla Pharmaceutical Company; San Diego, Calif) was used to treat vasoplegia after TAAAR to maintain a satisfactory MAP and prevent SCD.

Source: JTCVS Techniques

DOI: 10.1016/j.xjtc.2020.08.007

Authors: Subhasis Chatterjee, Ourania Preventza, Mariam C. Mousavi, Vicente Orozco-Sevilla, Scott A. LeMaire, Joseph S. Coselli

Institution: Baylor College of Medicine

Language: English

Topic: Aortic Disease and Treatment Approaches

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,553